These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19914435

  • 1. Effective desensitization to imiglucerase in a patient with type I Gaucher disease.
    Peroni DG, Pescollderungg L, Piacentini GL, Cassar W, Boner AL.
    J Pediatr; 2009 Dec; 155(6):940-1. PubMed ID: 19914435
    [Abstract] [Full Text] [Related]

  • 2. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
    Erdoğdu D, Gelincik A, Canbaz B, Colakoğlu B, Büyüköztürk S, Tanakol R.
    Int Arch Allergy Immunol; 2013 Dec; 160(2):215-7. PubMed ID: 23018845
    [Abstract] [Full Text] [Related]

  • 3. Successful rapid desensitization to imiglucerase in an adult patient with Gaucher disease and documented IgE-mediated hypersensitivity.
    Tsilochristou O, Gkavogiannakis NA, Ioannidou EN, Makris M.
    J Allergy Clin Immunol Pract; 2015 Dec; 3(4):624-6. PubMed ID: 25609344
    [No Abstract] [Full Text] [Related]

  • 4. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
    Aviner S, Levy Y, Yaniv I, Cohen IJ.
    Blood Cells Mol Dis; 1999 Apr; 25(2):92-4. PubMed ID: 10389590
    [Abstract] [Full Text] [Related]

  • 5. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K, Richards S, Yee J, Smith SE, Kingma W.
    Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
    [Abstract] [Full Text] [Related]

  • 6. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 7. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 9. Protocol for Desensitization to Trastuzumab in a Patient With Anaphylaxis and Stage IV Breast Cancer: A Case Report.
    de Lira-Quezada CE, Villarreal-González RV, González-Díaz SN, Acuña-Ortega N.
    J Investig Allergol Clin Immunol; 2020 Apr; 30(5):376-377. PubMed ID: 32376514
    [No Abstract] [Full Text] [Related]

  • 10. Successful Infusion of Obinutuzumab by Desensitization: A Case of Anaphylactic Shock During Desensitization.
    Kim KW, Chung S, Lee SY, Yoon SS, Kang HR.
    J Investig Allergol Clin Immunol; 2020 Apr; 30(6):457-459. PubMed ID: 32376522
    [No Abstract] [Full Text] [Related]

  • 11. [Diagnosis, prevention and treatment of drug allergy].
    Patkowski J, Małolepszy J, Ciepichał J.
    Postepy Hig Med Dosw; 1987 Apr; 41(1):45-53. PubMed ID: 3299343
    [No Abstract] [Full Text] [Related]

  • 12. Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease.
    Serratrice C, Swiader L, Serratrice J, Weiller PJ, Verrot D.
    Eur J Intern Med; 2012 Mar; 23(2):e71-2. PubMed ID: 22284262
    [No Abstract] [Full Text] [Related]

  • 13. Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.
    Chien YH, Lee NC, Tsai FJ, Chao MC, Hwu WL.
    Mol Genet Metab; 2010 Sep; 101(1):90-1. PubMed ID: 20580583
    [No Abstract] [Full Text] [Related]

  • 14. Imiglucerase treatment in Gaucher's disease.
    Shah U, Nadeem N, Husen Y, Fadoo Z.
    J Ayub Med Coll Abbottabad; 2007 Sep; 19(2):56-9. PubMed ID: 18183722
    [Abstract] [Full Text] [Related]

  • 15. Anaphylaxis to chemotherapy and monoclonal antibodies.
    Castells MC.
    Immunol Allergy Clin North Am; 2015 May; 35(2):335-48. PubMed ID: 25841555
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment.
    DuBuske I, Schmidlin K, Bernstein JA.
    Ann Allergy Asthma Immunol; 2021 Jan; 126(1):96-98. PubMed ID: 32866621
    [No Abstract] [Full Text] [Related]

  • 18. Anaphylactoid reaction to high-dose methotrexate and re-administration after a successful desensitization.
    Caldeira T, Costa V, Silva I, Oliva T, Norton L.
    Pediatr Hematol Oncol; 2008 Mar; 25(2):131-4. PubMed ID: 18363180
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Diagnosis and treatment of anaphylactic/anaphylactoid reactions.
    Levy JH, Levi R.
    Monogr Allergy; 1992 Mar; 30():130-44. PubMed ID: 1280764
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.